McKnight Vice Chair, Dr. Madhav Thambisetty, MD, PhD, Invited to Present at the NIH Director’s Seminar Series

Valerie PatmintraEvents

Dr. Madhav Thambisetty

From Mechanisms to Medicines: Realizing the DREAM of an Alzheimer’s Cure

September 14, 2020 – Madhav Thambisetty, MD, PhD, Vice Chair of the McKnight Brain Research Foundation and Senior Investigator and Chief of the Clinical and Translational Neuroscience Section Laboratory of Behavioral Neuroscience at the National Institute on Aging, has been invited to present “From Mechanisms to Medicines: Realizing the DREAM of an Alzheimer’s Cure” as part of the National Institute of Health’s Director’s Seminar Series.

The seminar will take place Friday, September 18, 2020 from 12:00-1:00pm Eastern via NIH Videocast:

About the lecture:

The repeated failures of disease-modifying treatments for Alzheimer’s disease (AD) have increased the urgency to identify novel therapeutic targets and biomarkers for AD and related dementias (ADRD).

Dr. Thambisetty’s Clinical and Translational Neuroscience Section has applied a systems biology approach leveraging deep molecular phenotyping by multi-OMICs methods in brain and blood in combination with multi-modal neuroimaging and epidemiological analyses to identify abnormal metabolic pathways in ADRD associated with severity of pathology and expression of clinical symptoms. These studies have added to a growing body of evidence that AD is a pervasive metabolic disorder with dysregulation in multiple interacting pathways. Dr. Thambisetty’s findings have uncovered plausible therapeutic targets for ADRD from these dysregulated metabolic pathways.

The Clinical and Translational Neuroscience Section has used large chemi-informatics databases to identify drugs that target genetic regulators of these pathways and have nominated several commonly used FDA-approved drugs as candidate AD treatments. Dr. Thambisetty’s lab has initiated analyses to test whether exposure to these drugs in large real-world clinical datasets containing >20 million older individuals is associated with altered risk of incident AD/dementia in the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study. 

To watch the lecture online, please visit

Share this post: